CN1639137A - 取代的3－苯基－5－烷氧基－1,3,4－噁二唑－2－酮、其制备及其在药物中的用途 - Google Patents

取代的3－苯基－5－烷氧基－1,3,4－噁二唑－2－酮、其制备及其在药物中的用途 Download PDF

Info

Publication number
CN1639137A
CN1639137A CNA038047837A CN03804783A CN1639137A CN 1639137 A CN1639137 A CN 1639137A CN A038047837 A CNA038047837 A CN A038047837A CN 03804783 A CN03804783 A CN 03804783A CN 1639137 A CN1639137 A CN 1639137A
Authority
CN
China
Prior art keywords
formula
alkyl
alkoxy
phenyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038047837A
Other languages
English (en)
Chinese (zh)
Inventor
K·舍纳芬格
S·佩特里
G·米勒
A·鲍尔
H·霍伊尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Publication of CN1639137A publication Critical patent/CN1639137A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
CNA038047837A 2002-02-28 2003-02-14 取代的3－苯基－5－烷氧基－1,3,4－噁二唑－2－酮、其制备及其在药物中的用途 Pending CN1639137A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10208987A DE10208987A1 (de) 2002-02-28 2002-02-28 Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxidiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen
DE10208987.6 2002-02-28

Publications (1)

Publication Number Publication Date
CN1639137A true CN1639137A (zh) 2005-07-13

Family

ID=27740558

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038047837A Pending CN1639137A (zh) 2002-02-28 2003-02-14 取代的3－苯基－5－烷氧基－1,3,4－噁二唑－2－酮、其制备及其在药物中的用途

Country Status (22)

Country Link
EP (1) EP1480960B1 (enExample)
JP (1) JP4486363B2 (enExample)
KR (1) KR20040095240A (enExample)
CN (1) CN1639137A (enExample)
AR (1) AR038701A1 (enExample)
AT (1) ATE557012T1 (enExample)
AU (1) AU2003226977A1 (enExample)
BR (1) BR0307921A (enExample)
CA (1) CA2477031A1 (enExample)
CO (1) CO5611146A2 (enExample)
DE (1) DE10208987A1 (enExample)
HR (1) HRP20040782A2 (enExample)
HU (1) HUP0402671A3 (enExample)
IL (1) IL163683A0 (enExample)
MA (1) MA27172A1 (enExample)
MX (1) MXPA04007960A (enExample)
NO (1) NO20044090L (enExample)
PE (1) PE20030928A1 (enExample)
PL (1) PL370423A1 (enExample)
RU (1) RU2004128933A (enExample)
TW (1) TW200400951A (enExample)
WO (1) WO2003072555A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074822B2 (en) 2004-02-23 2006-07-11 Solvay Pharmaceuticals Gmbh Alkyl carbamate-substituted β-lactones, process for their preparation, and pharmaceutical compositions containing them
CA2585175A1 (en) 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
CA2710743A1 (en) * 2007-12-27 2009-07-09 Bial-Portela & Ca., S.A. 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use
TW201028406A (en) 2008-12-23 2010-08-01 Bial Portela & Ca Sa 5-O-substituted 3-N-aryl-1,3,4-oxadiazolones for medical use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19942354A1 (de) * 1999-09-04 2001-03-08 Aventis Pharma Gmbh Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneimitteln
WO2001066531A1 (de) * 2000-03-07 2001-09-13 Aventis Pharma Deutschland Gmbh Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one (und) ihre verwendung zur hemmung der hormonsensitiven lipase

Also Published As

Publication number Publication date
HRP20040782A2 (en) 2005-02-28
NO20044090L (no) 2004-11-04
PE20030928A1 (es) 2003-12-17
EP1480960B1 (de) 2012-05-09
EP1480960A1 (de) 2004-12-01
AU2003226977A1 (en) 2003-09-09
AR038701A1 (es) 2005-01-26
JP4486363B2 (ja) 2010-06-23
CO5611146A2 (es) 2006-02-28
KR20040095240A (ko) 2004-11-12
MA27172A1 (fr) 2005-01-03
RU2004128933A (ru) 2005-04-20
BR0307921A (pt) 2004-12-21
MXPA04007960A (es) 2004-11-26
ATE557012T1 (de) 2012-05-15
TW200400951A (en) 2004-01-16
IL163683A0 (en) 2005-12-18
HUP0402671A2 (hu) 2005-04-28
WO2003072555A1 (de) 2003-09-04
CA2477031A1 (en) 2003-09-04
DE10208987A1 (de) 2003-09-11
JP2005519085A (ja) 2005-06-30
HUP0402671A3 (en) 2006-07-28
PL370423A1 (en) 2005-05-30

Similar Documents

Publication Publication Date Title
CN1218936C (zh) 甲酰胺取代的苯基脲衍生物以及用于将其作为药物的制备方法
CN1771247A (zh) 肟衍生物及其作为药物活性试剂的用途
CN1176080C (zh) 茚并一,萘并一和苯并环庚二氢噻唑衍生物,它们的制备以及它们作为降低食欲药的用途
CN1423640A (zh) 在8a位被取代的8,8a－二氢茚并[1,2－d]噻唑衍生物、它们的制备方法和它们作为药物、例如减食欲剂的用途
CN1378539A (zh) 硫代氨基甲酸衍生物
CN1305465A (zh) 芳基链烷酰基哒嗪化合物
CN1406234A (zh) 在2－位携带具有磺酰胺结构或砜结构的取代基的8,8a－二氢茚并[1,2－d]噻唑衍生物、它们的制备方法和它们作为药物的用途
CN1610683A (zh) 作为磷酸酶抑制剂的嘧啶并三嗪
CN1018644B (zh) 二唑-烷基-嘌呤衍生物的制备方法
CN1729173A (zh) N－(吲哚乙基)环胺化合物
CN1152024C (zh) 取代的3－苯基－5－烷氧基－1,3,4－噁二唑－2－酮及其作为脂酶抑制剂的用途
CN1675193A (zh) 1－甲基－2－(4－脒基苯基氨甲基)－苯并咪唑－5－基－羧酸－(n－2－吡啶基－n－2－羟基羰基乙基－酰胺的新颖前药，其制法及其作为药物制剂的用途
CN1125575A (zh) 粘附受体拮抗剂
CN1095836C (zh) 苯并咪唑衍生物
CN1212835C (zh) 含异羟肟酸酯的半胱氨酸和丝氨酸蛋白酶抑制剂
CN1639137A (zh) 取代的3－苯基－5－烷氧基－1,3,4－噁二唑－2－酮、其制备及其在药物中的用途
CN1145613C (zh) 邻苯二酚腙衍生物及其制备方法以及含该衍生物的药物组合物
CN88101782A (zh) 抗心律不齐药
CN1852906A (zh) 新化合物
CN1638766A (zh) 取代的3－苯基－5－烷氧基－1,3,4－噁二唑－2－酮在制备抑制胰脂肪酶的药物中的用途
CN1875018A (zh) 制备噻唑烷二酮的方法
CN1775767A (zh) 新的苯并噻二嗪化合物及其制备方法和含有它们的药物组合物
HK1075250A (en) Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, the production thereof and their use in medicaments
CN1764660A (zh) 新型噁唑衍生物,它们的制造和作为药物制剂的用途
CN1045778A (zh) 取代的(喹啉-2-基甲氧基)苯基-n，n′-磺酰脲、其制备方法及其在药物中之应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1075250

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1075250

Country of ref document: HK